|
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase III, Phase II | Supportive care, Treatment | Active | Not specified | Levosta-CBF-02/04
NCT00215007 |
Trial Description
Summary The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT). Eligibility Criteria Inclusion Criteria: Exclusion Criteria:
Trial Contact Information
Trial Lead Organizations/Sponsors Charite University Hospital - Campus Virchow Klinikum | Igor Wolfgang Blau, Dr. |  | Study Chair |
Trial Sites
|
|
|
|
| Germany |
|
| |
Berlin |
|
| | | | | | | | Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin |
| | | Igor Wolfgang Blau | |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00215007
Information obtained from ClinicalTrials.gov on March 18, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
